Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel CCR1 antagonists with improved metabolic stability.

Matthew F Brown1, Mike Avery, William H Brissette

  • 1Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. matthew_f_brown@groton.pfizer.com

Bioorganic & Medicinal Chemistry Letters
|April 15, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of hard electrophilic reactive metabolites formed from alicyclic amines using glutathione trapping.

Xenobiotica; the fate of foreign compounds in biological systems·2026
Same author

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

Journal of cachexia, sarcopenia and muscle·2026
Same author

A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer.

ESMO open·2026
Same author

Fragmentation Resilience Energy Mass Spectrometry (FREMS): Methods Validation and Compound Differentiation.

Molecules (Basel, Switzerland)·2026
Same author

Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor.

Journal of medicinal chemistry·2025
Same author

Socioeconomic disparities and osteoarthritis impact hormone therapy adherence in breast cancer.

Breast (Edinburgh, Scotland)·2025

Novel CCR1 antagonists were synthesized and evaluated for biological activity and pharmacokinetic properties. These compounds show potential for therapeutic applications by targeting chemokine receptor 1.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Immunology

Background:

  • Chemokine receptor 1 (CCR1) is implicated in inflammatory diseases.
  • Developing targeted therapies for CCR1-mediated conditions is a significant area of research.

Purpose of the Study:

  • To synthesize novel compounds targeting CCR1.
  • To evaluate the biological activity and pharmacokinetic profiles of these novel antagonists.

Main Methods:

  • Chemical synthesis of novel CCR1 antagonists.
  • In vitro assays to assess biological activity.
  • In vivo studies to determine pharmacokinetic parameters.

Main Results:

  • Successful synthesis of a new series of CCR1 antagonists.

Related Experiment Videos

  • Demonstrated significant biological activity in relevant assays.
  • Characterized favorable pharmacokinetic profiles, indicating potential for drug development.

    • Conclusions:

    • The novel CCR1 antagonists possess promising biological activity and suitable pharmacokinetic properties.
    • These compounds represent potential therapeutic candidates for inflammatory diseases mediated by CCR1.